Atopic Dermatitis/Atopic Eczema – Landscape & Forecast – Disease Landscape & Forecast
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical therapies (e.g., corticosteroids) are often effective for mild disease but suffer from suboptimal safety, tolerability, and compliance. More-effective therapies for topical-refractory patients and, more generally, those with moderate to severe AD are also sorely needed and are a key focus of the burgeoning AD pipeline. Pfizer’s nonsteroidal topical Eucrisa (crisaborole) and Sanofi / Regeneron’s injectable biologic Dupixent (dupilumab) are the first in a series of new entrants we expect to transform the AD treatment algorithm. This report provides a comprehensive analysis of AD patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of emerging drugs.
QUESTIONS ANSWERED
- How large are the mild, moderate, and severe AD subpopulations, and how will they change by 2029? How well are these populations served by current AD therapies?
- How have the launches of Pfizer’s Eucrisa and Sanofi / Regeneron’s Dupixent altered the AD treatment landscape?
- What emerging therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
- What are the greatest unmet needs, and to what degree will emerging therapies in the pipeline address these needs?
PRODUCT DESCRIPTION
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Atopic Dermatitis/Atopic Eczema - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q3 2021
- September 2021
- August 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- March 2021
- February 2021
- Q4 2020
- October 2020
- Q3 2020
- September 2020
- Q2 2020
- May 2020
- Q4 2019
- December 2019
- Q3 2021
- Key Findings
- Atopic Dermatitis - Key Findings - October 2020
- December 2019
- Atopic Dermatitis - Key Findings - October 2020
- Market Outlook
- Key Findings
- Market Share of Drug Classes for Atopic Dermatitis: 2019
- Market Share of Drug Classes for Atopic Dermatitis: 2029
- Atopic Dermatitis SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- What Factors Are Driving the Market for Atopic Dermatitis?
- What Factors Are Constraining the Market for Atopic Dermatitis?
- Drug-Class-Specific Trends
- Major-Market Sales of IL-4 / IL-13 Inhibitors: 2019-2029
- Major-Market Sales of IL-31 Inhibitors: 2019-2029
- Major-Market Sales of JAK Inhibitors: 2019-2029
- Major-Market Sales of Topical JAK Inhibitors: 2019-2029
- Major-Market Sales of Topical Phosphodiesterase-4 Inhibitors: 2019-2029
- U.S. Sales of Neurokinin-1 Receptor Antagonists: 2019-2029
- Major-Market Sales of Topical Calcineurin Inhibitors: 2019-2029
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Clinical Presentation
- Atopic Dermatitis Risk and Protective Factors
- Key Risk Factors for Atopic Dermatitis
- Protective Factors in Atopic Dermatitis
- Social and Economic Burden of Atopic Dermatitis
- Atopic Dermatitis Comorbidities
- Cutaneous Immunity
- The Skin Barrier
- Skin Barrier Defects
- Key Skin Barrier Proteins Mutated in Atopic Dermatitis
- Altered Immune Reactivity and the Skin Microbiome
- Key Pathways and Drug Targets
- Disease Overview
- Epidemiology Overview
- Key Findings
- Key Updates
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Prevalence of Atopic Dermatitis
- Total Prevalent Cases of Atopic Dermatitis: 2019-2029
- Disease Definition
- Methods
- Sources Used for Severity of 12-Month Total Prevalent Atopic Dermatitis
- Number of 12-Month Total Prevalent Cases of Atopic Dermatitis in the Major Pharmaceutical Markets by Severity: 2019-2029
- Diagnosed Prevalent Cases of Atopic Dermatitis: 2019-2029
- Disease Definition
- Methods
- Sources Used for Severity of Diagnosed 12-Month Prevalent Atopic Dermatitis
- Number of Diagnosed 12-Month Total Prevalent Cases of Atopic Dermatitis in the Major Pharmaceutical Markets by Severity: 2019-2029
- Drug-Treated Diagnosed Prevalent Cases of Mild Atopic Dermatitis: 2019-2029
- Drug-Treated Diagnosed Prevalent Cases of Moderate Atopic Dermatitis: 2019-2029
- Drug-Treated Diagnosed Prevalent Cases of Severe Atopic Dermatitis: 2019-2029
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Atopic Dermatitis
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drugs Classes Used for Atopic Dermatitis
- Current Treatments Used for Atopic Dermatitis
- Market Events Impacting the Use of Key Current Therapies for Atopic Dermatitis
- Clinical Trial Outcomes for Cibinqo
- Advantages and Disadvantages of Cibinqo
- Key Results From Select Clinical Trials Investigating Cibinqo for the Treatment of Atopic Dermatitis
- Ongoing Clinical Development of Cibinqo
- Key Ongoing Clinical Trials of Cibinqo in the Treatment of Atopic Dermatitis
- Expert Insight: Cibinqo
- Rinvoq
- Clinical Trial Outcomes for Rinvoq
- Advantages and Disadvantages of Rinvoq
- Key Results From Select Clinical Trials Investigating Rinvoq for the Treatment of Atopic Dermatitis
- Ongoing Clinical Development of Rinvoq
- Key Ongoing Clinical Trials of Rinvoq in the Treatment of Atopic Dermatitis
- Expert Insight: Rinvoq
- Olumiant
- Advantages and Disadvantages of Olumiant
- Key Results From Select Clinical Trials Investigating Olumiant for the Treatment of Atopic Dermatitis
- Ongoing Clinical Development of Olumiant
- Key Ongoing Clinical Trials of Olumiant in the Treatment of Atopic Dermatitis
- Expert Insight: Olumiant
- Advantages and Disadvantages of Eucrisa / Staquis
- Key Results from Select Phase III or Phase IV Clinical Trials of Eucrisa / Staquis for the Treatment of Atopic Dermatitis
- Ongoing Clinical Development of Eucrisa / Staquis
- Key Ongoing Clinical Trials of Eucrisa / Staquis in the Treatment of Atopic Dermatitis
- Expert Insight: Eucrisa / Staquis
- Advantages and Disadvantages of Dupixent
- Outcomes from Key Phase III Clinical Trials of Dupixent
- Ongoing Clinical Development
- Key Ongoing Clinical Trials of Dupixent in the Treatment of Atopic Dermatitis
- Expert Insight: Use of Dupixent in the Treatment of Atopic Dermatitis
- Expert Insight: Dupixent
- Key Results From Phase III Clinical Trials Investigating Corectim for the Treatment of Atopic Dermatitis
- Advantages and Disadvantages of Opzelura
- Clinical Trial Outcomes for Opzelura
- Key Results From Select Clinical Trials Investigating Opzelura for the Treatment of Atopic Dermatitis
- Ongoing Clinical Development of Opzelura
- Key Ongoing Clinical Trials of Opzelura in the Treatment of Atopic Dermatitis
- Expert Insight: Opzelura
- Advantages and Disadvantages of Pimecrolimus
- Expert Insight: Use of Pimecrolimus in the Treatment of Atopic Dermatitis
- Advantages and Disadvantages of Topical Tacrolimus
- Expert Insight: Use of Topical Tacrolimus in the Treatment of Atopic Dermatitis
- Potency and Formulations of Corticosteroids Commonly Used in the Treatment of Atopic Dermatitis
- Advantages and Disadvantages of Topical Corticosteroids
- Expert Insight: Use of Topical Corticosteroids in the Treatment of Atopic Dermatitis
- Advantages and Disadvantages of Conventional Oral Immunosuppressants
- Expert Insight: Use of Conventional Oral Immunosuppressant Agents in the Treatment of Atopic Dermatitis
- Advantages and Disadvantages of Emollients
- Expert Insight: Use of Emollients in the Treatment of Atopic Dermatitis
- Advantages and Disadvantages of Phototherapy
- Expert Insight: Use of Phototherapy in the Treatment of Atopic Dermatitis
- Medical Practice
- Overview
- Factors Influencing Drug Selection in Atopic Dermatitis
- Treatment Decision Tree for Atopic Dermatitis: United States
- Treatment Decision Tree for Atopic Dermatitis: Europe
- Treatment Decision Tree for Atopic Dermatitis: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Atopic Dermatitis
- Top Unmet Needs in Atopic Dermatitis: Current and Future Attainment
- Expert Insight: Unmet Need in Atopic Dermatitis
- Emerging Therapies
- Key Findings
- Pipeline Trends in Atopic Dermatitis
- Key Emerging Therapies
- Key Therapies in Development for Atopic Dermatitis
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Atopic Dermatitis
- Lebrikizumab Profile
- Key Ongoing Clinical Trials of Lebrikizumab in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for Lebrikizumab
- Expert Insight: Lebrikizumab
- Expectations for Launch and Sales Opportunity of Lebrikizumab in Atopic Dermatitis
- Tralokinumab Profile
- Key Ongoing Clinical Trials of Tralokinumab in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for Tralokinumab
- Expert Insight: Tralokinumab
- Expectations for Launch and Sales Opportunity of Tralokinumab in Atopic Dermatitis
- Key Results from Select Clinical Trials Investigating Nemolizumab for the Treatment of Atopic Dermatitis
- Key Ongoing Clinical Trials of Nemolizumab in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for Nemolizumab
- Expert Insight: Nemolizumab
- Expectations for Launch and Sales Opportunity of Nemolizumab in Atopic Dermatitis
- Tradipitant Profile
- Key Ongoing Clinical Trials of Tradipitant in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for Tradipitant
- Expert Insight: Tradipitant
- Expectations for Launch and Sales Opportunity of Tradipitant in Atopic Dermatitis
- Delgocitinib Profile
- Key Ongoing Clinical Trials of Delgocitinib in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for Delgocitinib
- Expert Insight: Delgocitinib
- Expectations for Launch and Sales Opportunity of Delgocitinib in Atopic Dermatitis
- Lotamilast Profile
- Analysis of the Clinical Development Program for Lotamilast
- Expert Insight: Lotamilast
- Expectations for Launch and Sales Opportunity of Lotamilast in Atopic Dermatitis
- Key Results from Select Clinical Trials Investigating Difamilast for the Treatment of Atopic Dermatitis
- Key Ongoing Clinical Trials of Difamilast in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for Difamilast
- Expert Insight: Difamilast
- Expectations for Launch and Sales Opportunity of Difamilast in Atopic Dermatitis
- DS-107 Profile
- Key Ongoing Clinical Trials of DS-107 in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for DS-107
- Expert Insight: DS-107
- Expectations for Launch and Sales Opportunity of DS-107 in Atopic Dermatitis
- Tapinarof Profile
- Analysis of the Clinical Development Program for Tapinarof
- Expert Insight: Tapinarof
- Expectations for Launch and Sales Opportunity of Tapinarof in Atopic Dermatitis
- KY1005
- KY1005 Profile
- Analysis of the Clinical Development Program for KY1005
- Expert Insight: KY1005
- Expectations for Launch and Sales Opportunity of KY1005 in Atopic Dermatitis
- ISB-830
- ISB-830 Profile
- Key Ongoing Clinical Trials of ISB-830 in the Treatment of Atopic Dermatitis
- Analysis of the Clinical Development Program for ISB-830
- Expert Insights: ISB-830
- Expectations for Launch and Sales Opportunity of ISB-830 in Atopic Dermatitis
- Early-Phase Pipeline Analysis
- Select Compounds in Early-Phase Development for Atopic Dermatitis
- Key Discontinuations and Failures in Atopic Dermatitis
- Expert Insight: Key Discontinuations and Failures
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Atopic Dermatitis: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Atopic Dermatitis: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Atopic Dermatitis: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Atopic Dermatitis
- Brands, Marketers, and Generic Availability of Key Therapies for Atopic Dermatitis: by Market
- Atopic Dermatitis Bibliography
- Key Updates
Andrew Russell, Ph.D., is a business insights analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. In this role, he authors reports that distill the findings of his research into pharmaceutical markets related to autoimmune disease and bacterial infection. He worked previously in neurodegenerative disease research at Brigham and Women’s Hospital in Boston. He holds a Ph.D. in cellular and molecular biology from Brandeis University.